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Human papillomavirus type 33 (HPV-33) pseudovirus infection is a slow process dependent on the initial interaction with
cell-surface heparan sulfate (T. Giroglou, L. Florin, F. Schafer, R. E. Streeck, and M. Sapp, 2001a, J. Virol. 75, 1565–1570). We
have now further dissected the initial steps of pseudovirus uptake using removal of cell-surface proteoglycans and selective
inhibition of entry pathways. Treatment of cells with heparinase I, but not with phosphoinositol-specific phospholipase C
(PIPLC), prevented binding of papillomavirus-like particles and infection with HPV-33 pseudovirions, indicating that GPI-linked
proteoglycans (glypicans) are not required for productive infection. The slow entry of pseudovirions was inhibited by
cytochalasin D and nocodazole in a concentration-dependent manner, suggesting actin polymerization and intact microtubuli
be required. Inhibitors of the caveolae-mediated uptake did not significantly affect pseudoinfection. Interestingly, pseudo-
infection was blocked by selective inhibitors of endosomal acidification up to 12 h postinfection. Together, our results suggest
that binding of HPV pseudovirions to heparan sulfate proteoglycans, most likely syndecans, is followed by delayedINTRODUCTION
Papillomaviruses are nonenveloped epitheliotropic vi-
ruses exclusively replicating in keratinocytes of the skin
and mucosa. Their DNA genome of approximately 8000
bp is encapsidated by the major and minor capsid pro-
teins, L1 and L2. Although the etiological role of human
papillomavirus (HPV) in the development of cervical in-
traepithelial neoplasia and invasive cancer is well estab-
lished, the initial steps of HPV infections are far from
being understood. Due to difficulties in generating pap-
illomaviruses in vitro, most investigations addressing
virus–receptor interactions were restricted to binding
studies with virus-like particles (VLPs), and the identity of
putative HPV-specific receptor proteins is still quite con-
troversial. By binding studies, attachment of HPV-6 VLPs
to the alpha-6 integrin was reported and it was proposed
that this integrin may act as a general receptor for bind-
ing and entry of papillomaviruses (Evander et al., 1997;
McMillan et al., 1999). However, other groups have
shown alpha-6 integrin to be dispensable for HPV-11 VLP
binding to cells (Joyce et al., 1999), for bovine papilloma-
virus type 4 (BPV-4) infection (Sibbet et al., 2000), as well
as for HPV-16 and HPV-33 pseudoinfection (Giroglou et
al., 2001a). VLPs of HPV-11 were shown to bind to hep-
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Gutenberg-Universita¨t Mainz, Hochhaus am Augustusplatz, D-55101279arin and to cell-surface proteoglycans of keratinocytes
and Chinese hamster ovary cells via heparan sulfate
(Joyce et al., 1999). Since cell-surface proteoglycans bind
to a large number of proteins, their molecular interac-
tions have long been considered nonspecific. This per-
ception was challenged in recent years by a growing
body of evidence demonstrating that heparan sulfate
interactions with ligands depend on specific sequences
and positioning of heparan sulfate moieties (Park et al.,
2000).
Heparan sulfate proteoglycans (HSPGs) consist of het-
erogeneously sulfated unbranched polysaccharides
composed of repeating disaccharide subunits of hexu-
ronic acid and hexosamine, covalently linked to the pro-
teoglycan core through O-glycosidic linkages to serine
residues. Although HSPGs are ubiquitously distributed
within the extracellular matrix of most tissues and lo-
cated on the cell surface of most cells, their expression
is highly regulated and cell type and developmental
stage-specific. Glypicans and syndecans are the major
subfamilies of cell-surface HSPGs. Glypicans contain a
glycosyl-phosphatidyl-inositol (GPI) anchor, whereas
syndecans, the transmembrane group of HSPGs, are
physically connected with cytoskeletal components and
play important roles in signal transduction (Park et al.,
2000). Moreover, syndecans function as specific growth
factor receptors and are involved in cell–cell adhesion.
Interestingly, they also regulate proteolytic and lipolytic
pathways and can directly mediate the internalization ofinternalization via the endosomal pathway. © 2002 Elsevier S
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lipoproteins and other ligands through a noncoated pit
pathway. This HSPG-mediated pathway involves cluster-
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ing of proteoglycans in detergent-insoluble membrane
rafts (David, 1993; Carey, 1997; Williams and Fuki, 1997).
Using pseudovirions encapsidating a marker plasmid
coding for a dimeric green fluorescent protein fused to a
nuclear localization signal (GFP-NLS), we recently pro-
vided evidence that cell-surface HSPGs are not only
involved in HPV binding but are also necessary for in-
fection with HPV (Giroglou et al., 2001a). In the present
investigation we further specified the family of proteogly-
cans required for HPV binding and examined the putative
intracellular trafficking pathway used by HPV pseudoviri-
ons for productive infection by applying specific inhibi-
tors.
RESULTS
Glypicans are not required for HPV binding and
infection
We first assessed if both transmembrane HSPGs (syn-
decans) and GPI-linked HSPGs (glypicans), which are
linked to the external leaflet of the membrane through a
GPI moiety, do play a role in HPV binding. COS-7 cells
were either treated with heparinase I, phosphoinositol-
specific phospholipase C (PIPLC), or left untreated prior
to the exposure to HPV-33 L1L2 VLPs. Cell-bound VLPs
were visualized by Western blot analysis using the HPV
capsid protein L1-specific monoclonal antibody 33L1-7
(Fig. 1A). General removal of glycosaminoglycans by
treatment of cells with heparinase I resulted in a drastic
decrease in VLP binding, confirming the previously re-
ported involvement of heparan sulfate in HPV host cell
interactions (Joyce et al., 1999; Giroglou et al., 2001a). In
contrast, specific removal of GPI-linked glypicans by
hydrolysis of phosphatidylinositol with PIPLC did not
significantly affect VLP binding, suggesting that glypi-
cans are not the key players in HPV host–cell interac-
tions. Corresponding results were obtained in VLP-bind-
ing assays using human cervical epithelial HeLa cells
(data not shown). Activities of the applied reagents were
controlled by FACS analysis. Removal of cell-surface
HSPGs after treatment with heparinase I was monitored
using the heparan sulfate specific monoclonal antibody
F58-10E4 (Fig. 1B). As judged by comparison of mean
fluorescence data, cell-surface expression of HSPG on
COS-7 was more than twofold lower than that of most
HeLa cells. These heparan sulfate moieties on the cell
surface were completely removed by treatment with he-
parinase I on COS-7 cells and significantly reduced on
HeLa cells. Due to the lack of glypican-specific antibod-
ies, cleavage of GPI-linked glypicans and other GPI-
linked proteins by PIPLC was controlled by measuring
the cell-surface presentation of DAF/CD55 proteins. Di-
gestion with PIPLC (1 unit/ml) resulted in complete re-
moval of these GPI-anchored proteins from COS-7 and
HeLa cells (Fig. 1C). The influence of heparinase and
PIPLC treatment on HPV-33 pseudovirus infections is
demonstrated in Fig. 1D. One hour prior to infection with
pseudovirions, cells were pretreated with heparinase I or
FIG. 1. Role of cell surface proteoglycans in VLP binding and pseudovirus infection. One hour prior to binding or infection, cells were either treated
with heparinase I (2 units/ml) for removal of all glucosaminoglycans or phosphoinositol-specific phospholipase C (PIPLC; 1 unit/ml) for specific
removal of GPI-anchored glypicans. (A) ECL Western blot analysis of HPV-33 VLP binding to heparinase I or PIPLC-treated COS-7 cells, using the HPV
L1 capsid protein-specific monoclonal antibody 33L1-7. (B) FACS analysis of untreated and heparinase I treated COS-7 and HeLa cells. Expression
of cell surface HSPGs is monitored using the heparan sulfate specific monoclonal antibody F58-10E4. The filled profile represents the autofluores-
cence control. (C) Presence of the GPI-linked DAF/CD55 protein on PIPLC-treated COS-7 and HeLa cells, as measured by FACS analysis. (D) Infection
of heparinase I- or PIPLC-treated COS-7 cells with HPV-33 pseudovirions. Removal of GPI-linked proteoglycans does not reduce subsequent virus
infection. Histograms show means of three values plus standard deviations.
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PIPLC. Correlating with the VLP binding study (Fig. 1A),
pseudovirus infection of COS-7 cells was completely
abolished by digestion of cell-surface HSPGs with hepa-
rinase I but was not affected by removal of GPI-linked
glypicans with PIPLC.
Analysis of the pseudovirus pathway of infection
Transmembrane HSPGs, in particular syndecans, have
previously been shown to directly mediate binding, inter-
nalization, and lysosomal delivery of certain ligands
through a largely uncharacterized, coated pit-indepen-
dent pathway (Fuki et al., 1997). To investigate the mech-
anism of HPV internalization, COS-7 cells were infected
with HPV-33 pseudovirions in the presence of various
pathway-specific inhibitors. Previous postattachment
neutralization experiments by Giroglou et al. (2001a) had
shown that internalization of HPV pseudovirions is a very
slow process. Cell-surface-bound virions were still ac-
cessible to heparin and neutralizing antibodies several
hours after addition of pseudovirions to cells. Significant
inhibition of such slow internalization requires prolonged
exposure to specific inhibitors. Since many inhibitors of
internalization and cell regulation are rather cytotoxic
and cannot be applied for 20 h or more, we used three
different time windows for the application of inhibitors of
HPV internalization and infection. As shown in the sche-
matic diagram in Fig. 2A, inhibitors were applied for 6-h
intervals from 0–6, 3–9, and 6–12 h postinfection (p.i.),
covering the early phase of pseudovirus infection. With
this assay, infectious events in the presence or absence
of inhibitors can be monitored by fluorescence micros-
copy at 48–72 h p.i., counting cells with nuclear green
fluorescence due to expression of the pseudovirus-en-
coded GFP-NLS protein (Fig. 2B). After removal of inhib-
itors at the defined time points, residual virions can be
neutralized by addition of HPV-specific K53 antibodies to
restrict pseudovirus entry to the investigated time inter-
val.
Slow uptake of pseudovirions depends
on actin-polymerization
Interaction with the actin network is a characteristic
feature of the syndecan group of HSPGs, and internal-
ization of ligands via syndecan-1 was reported to be
dependent on an intact actin cytoskeleton (Fuki et al.,
1997). We therefore investigated the effect of cytochala-
sin D, a potent inhibitor of microfilaments (Miranda et al.,
1974), on HPV pseudovirus infection. As shown in Fig. 3A,
dose-dependent inhibitory effects were observed with
cytochalasin D present at 0.5, 1, and 5 M concentra-
tions. When the actin network was depolymerized as late
as 6–12 h p.i., a dose-dependent inhibitory effect on
infectivity was still observed, confirming the unusually
slow kinetics of pseudovirus internalization. Although the
effect of cytochalasin D was not as pronounced as 0–6 or
3–9 h p.i., pseudoinfection was still reduced by 78%
when cells were treated with 5 M cyto D. These data
demonstrate that the actin network plays a critical role in
the early steps of HPV pseudovirus infection.
Pseudovirus infection requires intact microtubuli
Recent electron microscopy data (Liu et al., 2000)
demonstrated the association of bovine papillomavirus-1
(BPV-1) virions with microtubules in the cytoplasm of
infected cells. To investigate the role of a putative micro-
tubule-mediated transport of HPV-33 pseudovirions,
COS-7 cells were treated with the microtubule-disrupting
agent nocodazole at 0–6, 3–9, and 6–12 h p.i. In all three
time windows tested, 5–20 M concentrations of no-
codazole were found to significantly affect pseudovirus
infectivity (Fig. 3B). In contrast to the early effect of the
actin inhibitor cytochalasin D, treatment with the micro-
tubuli-depolymerizing drug nocodazole seemed to be
most effective at 3–9 and 6–12 h p.i. These data indicate
that intact microtubuli are required up to the late steps of
pseudovirus entry.
Treatment with Nystatin does not impair pseudovirus
infection
Until recently (Murphy, 1996) papillomaviruses, polyoma-
viruses, and simian virus 40 (SV40), now belonging to sep-
FIG. 2. Application of specific inhibitors in the HPV-33 pseudovirus
infection system. (A) Schematic representation of the pseudoinfection
inhibition protocol. Inhibitors of various internalization pathways are
applied during three different time windows of pseudovirus infection:
0–6 h postinfection (p.i.), 3–9 and 6–12 h p.i. (B) COS-7 cells infected
with HPV-33 pseudovirions. Infectious events in the presence or ab-
sence of inhibitors are monitored counting cells with nuclear green
fluorescence (GFP-NLS). Pseudovirus infection is neutralized in the
presence of HPV-33 VLP-specific K53 antibodies.
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arate virus families, were all grouped into the Papovaviridae
family. The uptake of mouse polyomavirus as well as the
slow entry of SV40 were both shown to occur via caveolae
(Anderson et al., 1996; Richterova et al., 2001). Productive
infection with SV40 was inhibited in the presence of cho-
lesterol-depleting drugs, such as nystatin or PMA (Ander-
son et al., 1996). In contrast to infections by members of the
family Polyomaviridae, HPV-33 pseudoinfection is not sig-
nificantly affected by inhibitors of the caveolae pathway, as
shown by the infection inhibition assay presented in Fig.
3C. In the presence of nystatin at concentrations of 5, 10,
and 20 M, only a weak dose-dependent effect on HPV
pseudoinfections was observed in one of the three tested
time windows, at 3–9 h p.i. However, infection was not
reduced by more than 35% (Fig. 3C). At 0–6 and 6–12 h p.i.
pseudovirus infection was not prevented by the inhibitor
concentrations tested. Similar results were obtained in the
presence of the phorbol ester PMA, used at concentrations
of 1, 5, and 10 M. In contrast to its minimal effect on HPV
infection, the presence of such concentrations of nystatin
and phorbol myristic acid significantly affected our infec-
tions of HeLa cells with Echovirus 1 (data not shown), a
virus recently demonstrated to be internalized via caveolae
(Marjomaki et al., 2002). Therefore, it is unlikely that caveo-
lae contribute significantly to productive HPV internaliza-
tion.
FIG. 3. HPV-33 pseudovirus infection of COS-7 cells in the presence of specific inhibitors. Indicated concentrations of cytochalasin D (A),
nocodazole (B), and the cholesterol-sequestering drug nystatin (C) were added from 0–6, 3–9, or 6–12 h p.i., respectively. Infectious events were
determined 72 h.p.i. by fluorescence microscopy. Histograms show means of at least three values and standard deviations.
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Pseudovirus infection is blocked by bafilomycin A1
Ligands that are taken into cells by receptor-mediated
endocytosis are sorted somewhere in between early to
late endosomes. Infectious entry of most viruses that use
this endocytic pathway requires acidification of late en-
dosomes by vacuolar ATPases to trigger conformational
changes in the capsid structure for release of their
genome into the cytosol or perinuclear area. These
ATPases are effectively inhibited by the fungal drug
bafilomycin A1 (BFLA1). During the first 6 h p.i., as low as
50 nm (0.05 M) concentrations of BFLA1 were already
sufficient to completely prevent HPV pseudovirus infec-
tion (Fig. 4A). General toxic effects on pseudovirions or
host cells, caused by the highest concentration (5 M) of
BFLA1, were determined in separate experiments to be
in the range of less than 15% (data not shown), confirm-
ing the specificity of this endosomal inhibitor. In good
correlation with the slow kinetics of pseudovirus uptake,
infectivity at 3–9 and 6–12 h p.i. was still reduced in the
presence of BFLA1 from 90% (0.05 M) up to 98% (5 M),
suggesting that HPV pseudovirions are slowly internal-
ized via the endosomal/lysosomal pathway and depen-
dent on endosome acidification.
FIG. 4. HPV-33 pseudovirus infection of COS-7 cells in the presence of inhibitors of the endosomal/lysosomal pathway. Indicated concentrations
of various inhibitors were added from 0–6, 3–9, or 6–12 h p.i. Infectious events were determined 72 h p.i. by fluorescence microscopy. Histograms
show means of at least three values and standard deviations. (A) Infectivity in the presence of bafilomycin A1 (BFLA1), a specific inhibitor of vacuolar
proton ATPases. Infection is also abolished in the presence of lysosomotropic weak bases, such as chloroquine (B) or ammonium chloride (C).
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Lysosomotropic weak bases prevent pseudovirus
infection
In addition to the well-established inhibitory effect on
endosome acidification, BFLA1 was also reported to
affect infectivity of some viruses by trapping of the virus
in endosomal subcompartments which lack components
necessary for viral uncoating (Bayer et al., 1998). To
further investigate whether a low pH in endocytic vesi-
cles is really necessary for productive pseudovirus in-
fection, lysosomotropic weak bases were added to the
infection assay to raise the vesicular pH. A dose-depen-
dent inhibition of infection was observed in the presence
of chloroquine present from 0–6, 3–9, and 6–12 h p.i. at
nontoxic concentrations in the range from 5 to 25 M
(Fig. 4B). As shown in Fig. 4C, similar results were ob-
tained by treatment of infected cells with excessive con-
centrations (5, 10, and 20 mM) of the lysosomotropic
agent ammonium chloride (NH4Cl). We conclude from
these studies that HPV-33 pseudovirions employ the en-
dosomal pathway and require endosomal acidification
for productive infection.
DISCUSSION
Viruses can enter cells on various internalization path-
ways, and this variation may largely depend on the in-
teractions with primary attachment receptors. We and
others have previously shown that cell-surface heparan
sulfate is the primary attachment receptor for HPV and
crucial for pseudovirus infectivity (Joyce et al., 1999; Gi-
roglou et al., 2001a). Since treatment of cells with hepa-
rinase I, but not with PIPLC, abolishes pseudovirus in-
fection, heparan sulfates of the transmembrane group
rather than GPI-linked glypicans seem to be required for
the initiation of productive infection. The data presented
in this article further suggest that after primary attach-
ment to proteoglycans, HPV-33 pseudovirions are inter-
nalized into the endosomal/lysosomal compartment.
Some years ago, Mu¨ller et al. (1995) had reported that the
uptake of HPV VLP-reporter plasmid complexes was
enhanced in the presence of replication-defective ad-
enoviruses, possibly due to adenovirus-mediated lysis of
lysosomal membranes. Analyzing the effects of various
inhibitors in our HPV-33 pseudoinfection system, we
could show that HPV infection is prevented in the pres-
ence of compounds that raise the pH in endosomes,
such as BFLA1, chloroquine, or NH4Cl, demonstrating
that acidification of endosomal vesicles is important for
the release of virions into the cytosol. Energy depletion
by addition of both 0.1% sodium acid (NaN3) and 50 mM
2-desoxy-D-glucose also completely abolishes infection
(data not shown), corroborating the uptake of pseudoviri-
ons via the energy-dependent endosomal pathway.
Our studies with nocodazole demonstrate the require-
ment of intact microtubules for pseudovirus infectivity. It
was recently reported that nocodazole blocks nuclear
trafficking of BPV-1 when added up to 30 min after virus
binding (Liu et al., 2000). In contrast to the data with
BPV-1, HPV-33 pseudovirius infection was sensitive to
microtubuli-depolarization as late as 6–12 h p.i., indicat-
ing that pseudovirions are still transported from endo-
somes to the nucleus at that time. These data correlate
with the slow uptake and long accessibility of pseudoviri-
ons on the cell surface (Giroglou et al., 2001a) as well as
with the slow infection kinetics of HPV-11, BPV-1, and
CRPV (Christensen et al., 1995). This delay in the uptake
of HPV pseudovirions may be attributed to their initial
interactions with proteoglycans and slow conversion
from a heparin-sensitive to a heparin-resistent state of
binding.
Interestingly, Fuki et al. (1997) have previously demon-
strated that syndecans are able to directly mediate en-
docytosis of certain multimeric ligands by a novel, largely
uncharacterized pathway independent of caveolae and
coated pits. Such a syndecan-mediated entry proceeds
with a half-time of internalization of about 1 h and is
dependent on interactions with the actin cytoskeleton.
Our observation of inhibitory effects mediated by cy-
tochalasin D in the pseudovirus infection assay would be
consistent with syndecan-mediated internalization. The
delayed uptake, however, is unusual for syndecan-medi-
ated direct internalization and would rather suggest the
involvement of a secondary receptor protein. Although
we only provide indirect evidence for a role of syndecans
in HPV binding and uptake, we still consider this group of
proteoglycans as the prime candidate receptors for pro-
ductive infection with HPV. However, we cannot com-
pletely exclude the involvement of other, less-character-
ized HSPGs, such as perlecans or betaglycans. The slow
kinetics of pseudovirus internalization would also corre-
late with the time course of perlecan internalization but is
inconsistent with its sensitivity toward treatment with
cytochalasin D. Regarding betaglycans, which are mod-
ulators of the TGF-beta actions, direct internalization of
ligands has not been described so far. Based on our
data, it is tempting to speculate that a syndecan-medi-
ated internalization of pseudovirions may join the endo-
somal pathway at the stages of early to late endosomes.
Such syndecan-mediated entry pathways are still under
investigation (Fuki et al., 1997). However, the existence of
viral entry mechanisms other than via the established
pathways was recently demonstrated studying the new
two-step vesicular transport pathway of SV40 (Pelkmans
et al., 2001). Initial entry of SV40 via caveolae delivered
the virus into a new organelle, termed caveosome,
where the virus stayed for several hours until micro-
some-dependent transport to the perinuclear area oc-
cured.
In accordance with our data, it is also conceivable that
attachment of HPV pseudovirions is followed by transfer
to a secondary receptor which subsequently mediates
delayed internalization via receptor-mediated endocyto-
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sis. This would be consistent with the idea that synde-
cans primarily function as modulators or facilitators of
cell–ligand interactions. Many structurally different vi-
ruses and certain microbial agents have previously been
shown to utilize sulfated glycosaminoglycans, such as
heparan sulfate, for initial binding to target cells, but
most of these viruses require additional proteins for
internalization (Shieh et al., 1992; Compton et al., 1993;
Rostand and Esko, 1997; Shukla et al., 1999; Hilgard and
Stockert, 2000; Akula et al., 2001). A transfer of HPV
pseudovirions from the primary HSPG receptor to a sec-
ondary receptor protein is also supported by the finding
that the minor capsid protein L2 is not required for initial
virus binding to proteoglycans but is important for virus
infectivity (Unckell et al., 1997; Kawana et al., 1998).
Kawana et al. (2001) recently reported specific binding
and internalization of a L2-GFP fusion protein into HPV-
susceptible cells and postulated the presence of L2-
specific cell-surface receptors, different from those for
L1. The HPV capsid contains 360 copies of L1 but only
about 12 copies of L2 (Sapp et al., 1995; Trus, 1997). HPV
infection may therefore require specific virus sequestra-
tion by proteoglycan attachment receptors for efficient
presentation of certain L2 domains to a secondary re-
ceptor protein which may subsequently deliver the virus
to the classical endosomal pathway.
MATERIALS AND METHODS
Cell lines and chemicals
COS-7 and HeLa cells were grown in monolayers in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal calf serum. If not
stated otherwise, all chemicals were obtained from
Sigma. Stock solutions of cytochalasin D (4 mM), no-
codazole (10 mM), nystatin (5 mM), PMA (10 mM), and
bafilomycin A1 (10 M) were prepared in dimethyl sul-
foxide (DMSO). The final concentration of DMSO, which
was also added to control samples, was kept below 1%.
Stock solutions of chloroquine (10 mM) and ammonium
chloride (400 mM) were dissolved in DMEM and ad-
justed to pH 7.
VLP binding assay
HPV33 L1/L2 virus-like particles, produced by infection
of insect SF9 cells with recombinant baculoviruses, were
prepared essentially as described by Volpers et al.
(1994). COS-7 cell monolayers (5  105 cells) were ex-
posed to 70 ng HPV33 L1/L2 VLPs in DMEM for 1 h at
4°C. Unbound VLPs were removed by three washes with
PBS; cells were lysed in Laemmli sample buffer and
subjected to sodium dodecyl sulfate–polyacrylamid gel
electrophoresis (SDS–PAGE). After blotting onto nitrocel-
lulose membrane, cell-surface-bound HPV L1 protein
was detected by ECL Western blot analysis using mono-
clonal antibody 33L1-7 (Sapp et al., 1994) and horserad-
ish peroxidase-conjugated secondary antibodies.
Removal of cell surface proteoglycans
Heparan sulfate proteoglycans were removed from the
cell surface of COS-7 and HeLa cells by treatment with
heparinase I (Sigma). Cells were grown to 80% conflu-
ency in six-well plates, washed with DMEM without FCS,
and incubated with 2 units of heparinase I for 60 min at
37°C in heparinase I buffer (20 mM Tris–HCl, 50 mM
NaCl, 4 mM CaCl2, 0.01% BSA, pH 7.5). GPI-linked HSPGs
(glypicans) and GPI-linked DAF/CD55 proteins were re-
leased from the cell surface by treatment with phosphoi-
nositol-specific phospholipase C (1 unit/ml DMEM) for 60
min at 37°C.
Flow cytometry
Prior to processing for FACS analysis, cells were pre-
treated with heparinase I or PIPLC as described above
and detached with 25 mM EDTA in Ca2- and Mg2-free
PBS. Single-cell suspensions (5  105 cells) were fixed
for 10 min with 3.7% formaldehyde–PBS and incubated
on ice with primary antibodies for 30 min. Cell-surface
HSPGs were detected with the anti-heparan sulfate IgM
antibody F58-10E4 (10 g/ml; Seikagaku Corp., Japan),
followed by a 30-min incubation on ice with Cy2-labeled
antimouse IgM and IgG. Removal of GPI-linked proteins
by PIPLC was analyzed by measuring the expression
levels of the GPI-linked DAF protein. Cells were exposed
to the anti-DAF monoclonal antibody IF7 (obtained from
Jeff Bergelson, Philadelphia, PA) and subsequently incu-
bated with FITC-labeled anti-mouse IgG. Cells were
washed in FACS buffer (PBS–1% BSA–5 mM EDTA–0.01%
NaN3, pH 6.8), analyzed in a FACSCalibur (Becton–Dick-
enson) flow cytometer, and evaluated using either
CellQuest or WinMDI 2.8 software.
HPV pseudovirus infection assay
HPV-33 pseudovirions, containing the GFP-NLS en-
coding plasmid, were basically prepared as published
recently (Giroglou et al., 2001b). COS-7 cells were grown
in 24-well plates (5  104 cells/well) and infected with
pseudovirions in a total volume of 250 l PBS–100 g/ml
BSA, pH 6.8. After 1 h at 4°C the pseudovirions were
replaced by 1 ml supplemented culture medium. Subse-
quently, cells were grown for 72 h at 37°C before infec-
tious events were determined by counting cells with
nuclear green fluorescence.
Inhibition of infection
To characterize postadsorption steps leading to infec-
tious entry of HPV-33 pseudovirions, infections were per-
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formed in the presence of pathway-specific inhibitors.
Cytochalasin D, nocodazole, nystatin, PMA, bafilomycin
A1, chloroquine, and ammonium chloride were applied
for 6 h intervals from 0–6, 3–9, and 6–12 h p.i. As for the
0–6 h time interval, inhibitors were present during a
preincubation period of 30 min at 37°C prior to virus
addition, during virus attachment for 1 h at 4°C, as well
as during the following 6 h at 37°C, to cover the very
early events of putative virus internalization. For assess-
ment of inhibitory effects during 3–9 and 6–12 h p.i., cells
were initially cultured in medium without inhibitors, and
chemicals were added at the start of the indicated time
intervals and removed after 6 h by replacement of culture
media. Virions remaining on the cell surface at the end of
the investigated time intervals were neutralized by addi-
tion of HPV-specific K53 antibodies (1:300 dilution). GFP-
positive cells were already visible at 48 h p.i. and con-
tinuously monitored from 48 to 96 h p.i. For evaluation of
inhibitory effects, pseudovirions produced in the pres-
ence and absence of inhibitors were counted at 72 h p.i.
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